Peter Kuhn, PhD

University Professor, Dean's Professor of Biological Sciences and Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace and Mechanical Engineering and Urology

Image of Peter Kuhn, PhD
Is this your profile? Click to edit

Overview

Peter Kuhn joined the USC Dana and David Dornsife College of Letters, Arts and Sciences as Dean’s Professor of Biological Sciences in July 2014. Dr. Kuhn also has appointments as Professor of Medicine, Professor of Biomedical Engineering and Professor of Aerospace & Mechanical Engineering, a founding member of the Michelson Center for Convergent Biosciences at USC and is leading CSI-Cancer at USC. He is a scientist, educator and entrepreneur with a career long commitment in personalized medicine and individualized cancer patient care. He is focused on the redesign of cancer care. The first product from technology developed by Dr. Kuhn became available for prostate cancer care in June 2016. Dr. Kuhn’s strategy is to advance our understanding of the human body to improve the human condition for those affected by cancer. His research is shedding new light at how cancer spreads through the body and evolves over time. This new science will lead to a personalized care strategy that is biologically informed and clinically actionable. He is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 and his Ph.D. in 1995. He then moved to Stanford University where he joined the faculties of Medicine and Accelerator Physics as tenure track Assistant Professor. From 2002 to 2014 he established the Physics Oncology program at The Scripps Research in La Jolla, CA as tenured Associate Professor before joining USC in 2014. He has published over 200 peer scientific articles and patents resulting from his research.

Publications

  • Polyploid cancer cells reveal signatures of chemotherapy resistance. bioRxiv. 2024 Aug 23.. View in PubMed
  • Cells in the Polyaneuploid Cancer Cell State are Pro-Metastatic. bioRxiv. 2024 Jul 16.. View in PubMed
  • Aqueous Humor Liquid Biopsy as a Companion Diagnostic for Retinoblastoma: Implications for Diagnosis, Prognosis, and Therapeutic Options: Five Years of Progress. Am J Ophthalmol. 2024 07; 263:188-205.. View in PubMed
  • Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy. BJC Rep. 2024 Jun 27; 2(1):47.. View in PubMed
  • Liquid Biopsy Profiling with Multiple Tests in Patients with Metastatic Breast Cancer. J Mol Pathol (Basel). 2024 Jun; 5(2):199-214.. View in PubMed
  • PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2024 06; 30(6):1636-1644.. View in PubMed
  • Longitudinal tracking of circulating rare events in the liquid biopsy of stage III-IV non-small cell lung cancer patients. Discov Oncol. 2024 May 03; 15(1):142.. View in PubMed
  • A Systematic Approach toward Enabling Maximal Targeting Efficiency of Cell Surface Proteins with Actively Targeted SERS Nanoparticles. ACS Appl Mater Interfaces. 2024 Apr 03; 16(13):15847-15860.. View in PubMed
  • Blood-based liquid biopsy: A promising noninvasive test in diagnosis, surveillance, and prognosis of patients with upper tract urothelial carcinoma. Urol Oncol. 2024 04; 42(4):118.e9-118.e17.. View in PubMed
  • Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. NPJ Precis Oncol. 2024 Feb 15; 8(1):36.. View in PubMed